Lissett earned her PhD in Bioengineering at Rice University in collaboration with MD Anderson Cancer Center where she developed rapid nanoparticle-based assays for cancer detection. She was subsequently a postdoctoral research associate at UNC Chapel Hill in the Lineberger Comprehensive Cancer Center; her research involved engineering medical devices for localized cancer drug delivery. Before coming to cc-TDI, Lissett also worked as a faculty member at Virginia Tech where her research was focused on nanoparticle toxicity and the effects of cancer therapy on immune response. Lissett’s long-term career goal is to make significant contributions in translational medicine by examining limitations to current practices and designing feasible studies and technologies to address these limitations.
Charles Keller, MD
Scientific Director & Chief Mission Officer
